Analyst Price Targets — ZURA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 11:32 am | — | Wedbush | $15.00 | $6.01 | TheFly | Zura Bio initiated with an Outperform at Wedbush |
| April 3, 2025 10:12 am | Mitchell Kapoor | H.C. Wainwright | $3.00 | $1.09 | TheFly | Zura Bio price target lowered to $3 from $5 at H.C. Wainwright |
| November 8, 2024 6:47 pm | Yatin Suneja | Guggenheim | $15.00 | $4.58 | StreetInsider | Guggenheim Reiterates Buy Rating on Zura Bio Ltd. (ZURA) |
| September 5, 2024 6:09 am | Mitchell Kapoor | H.C. Wainwright | $5.00 | $3.95 | TheFly | Zura Bio initiated with a Neutral at H.C. Wainwright |
Latest News for ZURA
On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe autoimmune diseases.
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with…
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on May 13, 2026, the Company granted an inducement award consisting of an option to purchase up to 600,000…
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business…
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “We entered the second…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZURA.
U.S. House Trading
No House trades found for ZURA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.